Gsk Plc · LSE:GSK
Gsk — Shareholder Meeting (May 2021)
13 slides from Gsk's shareholder meeting presentation, May 5, 2021
Slide 1: Annual General Meeting
Emma Walmsley Chief Executive Officer Annual General Meeting 5 May 2021
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly t
Slide 3: On track to deliver strategic transformation
On track to deliver strategic transformation Focused on creating significant shareholder value with new companies 2017 2022 Innovation Invest in pipeline Sharpen commercial New GSK execution Performance Improve cash generation and investment prioritisation New Consumer Trust ESG leadership Healthcar
Slide 4: 2020 – a year like no other
2020 – a year like no other Vaccines and Supporting Impact COVID-19 therapeutics vaccine on 2020 collaboration manufacture performance 4
Slide 5: 2020: Strong Operating and Financial performance
2020: Strong Operating and Financial performance Impact from COVID-19 and earnings guidance achieved Sales Group turnover Free cash flow £34bn +3% 80p Total £5.4bn +7% dividend per share Earnings Per Share Total 115.5p +26% Adjusted 115.9p (4)% Percentage growth at CER; except free cash flow that is
Slide 6: Operating Performance: Pharmaceuticals
Operating Performance: Pharmaceuticals Total sales £17bn: down 1% – Insert pic Strong commercial Progress in Progress in execution in our HIV, new 2 drug Oncology, Blenrep New and specialty regimens more launch and Zejula products, up 12%* than doubled growing market share 2020 figures. CER growth r
Slide 7: Operating Performance: Vaccines
Operating Performance: Vaccines Total sales £7bn: down 1% Strong underlying Progress in Progress in demand for Influenza, up Meningitis, up 3% Shingrix, up 11% 37% 2020 figures. CER growth rates 7
Slide 8: Operating Performance: Consumer Healthcare
Operating Performance: Consumer Healthcare Total sales £10bn: up 14% Continued strong performance from our power brands 2020 figures. CER growth rates 8
Slide 9: Significant progress in 2020 to strengthen R&D pipeline
Significant progress in 2020 to strengthen R&D pipeline Building high-value biopharma pipeline focused on vaccines and specialty medicines 9 9 20 20 major pivotal studies assets in business approvals started late-stage development development deals 70% of research targets genetically validated | Sev
Slide 10: Strong R&D pipeline vaccines and medicines
Strong R&D pipeline 19 vaccines and 40 medicines First time in human/POM (Phase 1/1b) Proof of concept (Phase 1b/2) Pivotal (Phase 2/3)/ Registration 3858279* (CCL17 inhibitor) OA pain 3640254 (maturation inhibitor) HIV Benlysta + Rituxan SLE Vx Rx 3745417 (STING agonist) cancer 3228836* (HBV ASO) H
Slide 11: Building Trust: significant progress made
Building Trust: significant progress made Improving performance, reducing risk and increasing impact Inclusion and Environmental goals Global Health Diversity targets Image Healthy planet, healthy people 11
Slide 12: Delivering sustainable growth to shareholders
Delivering sustainable growth to shareholders Firmly on track 2021 will see further 2022 to deliver with our intention investment in our pipeline to separate into and new products to meaningful two new sustain long-term improvements companies competitive growth next year and launch Detailed prospect
Slide 13: Annual General Meeting
Emma Walmsley Chief Executive Officer Annual General Meeting 5 May 2021